Some Caution Over 'People’s Hope' Remdesivir As China Trials Progress
Although Gilead’s remdesivir shows promise against the coronavirus, efficacy is not guaranteed, one antiviral company executive tells Scrip, as multiple other potential therapies and vaccines move forward.
You may also be interested in...
BIO hosts summit to support collaborations on coronavirus vaccines and therapeutics, Vir advances COVID-19 antibody candidates, Gilead renounces orphan status for remdesivir, BMS joins Pfizer in pushing back investor meeting, and ASCO goes virtual.
The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.
Bayer's anti-malaria therapy chloroquine is being touted as a cheap, safe and effective drug for coronavirus. However the company's product is only made in Pakistan and a variety of import and export agreements need to be in place for other countries to get hold of it.